Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next ...

Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...
Le Lézard

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The ...
News-Medical.Net on MSN

Stress hormones may silence crucial neuronal genes through specific RNA molecules

What if the brain's response to stress could be read not in fleeting neurotransmitter bursts, but in the quieting of genes ...
360Dx

Qiagen to Acquire Single-Cell Omics Firm Parse Biosciences for Up to $280M; CEO Bernard to Depart

The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.
Healio

Potential ‘new paradigm’: COVID-19 mRNA vaccines boost response to cancer immunotherapy

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...